Analytical Data
-
Gene name
IFITM2
- Application
-
Alternative Names
DSPA2c; Dispanin subfamily A member 2c; Interferon-inducible protein 1-8D
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99J93
-
Expression Region
Met1~Phe144
-
Molecular Weight
19kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFITM2, or Interferon-Inducible Transmembrane Protein 2, is a member of the IFITM family, which plays a crucial role in the immune response and antiviral defense. It is primarily expressed in various tissues, including lymphocytes and epithelial cells, and is known to be upregulated by interferons during viral infections. Research has shown that IFITM2 inhibits the entry of several enveloped viruses, including influenza and HIV, by restricting their fusion with host cell membranes. This restriction occurs through its membrane-spanning domains, which alter the lipid composition and cellular microenvironment, thereby preventing successful viral infection. Furthermore, IFITM2 has been implicated in modulating various signaling pathways associated with inflammation and cell survival, highlighting its potential role in both antiviral immunity and cancer biology. Understanding the mechanisms by which IFITM2 functions can provide valuable insights into developing therapeutic strategies against viral infections and leveraging its activity in cancer treatment. The recombinant expression of IFITM2 allows for detailed studies into its structure-function relationship and paves the way for examining its possible applications in biotechnology and medicine. Researchers are actively exploring these avenues to harness IFITM2's properties for vaccine development and as a potential antiviral agent, thus making it a significant focus in the fields of immunology, molecular biology, and drug development. Overall, the study of IFITM2 and its recombinant forms is poised to contribute to a deeper understanding of host-pathogen interactions and the development of novel therapeutic approaches in combating infectious diseases.
